Responses
Regular and young investigator award abstracts
Immune-stimulants and immune modulators
587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.